President of Cardiac Rhythm & Neuromodulation Transitions to Special Projects Ahead of Potential Sale
Summary
Integer Holdings announced a key executive transition, moving its President of Cardiac Rhythm Management & Neuromodulation to a temporary special projects role with specific change-of-control provisions, signaling ongoing preparations related to its strategic review for a potential sale.
Key Events
-
Executive Role Change
Jim Stephens, President of Cardiac Rhythm Management & Neuromodulation, is transitioning to Executive Vice President, Special Projects, effective June 29, 2026.
-
Defined End Date
The new role has a defined end date of March 31, 2027, unless terminated earlier.
-
Change of Control Provision
If a Change of Control occurs before March 31, 2027, and Mr. Stephens remains employed, his separation will be considered a termination without Cause, triggering benefits under his existing Change of Control Agreement.
-
Incentive Eligibility
Mr. Stephens will not be eligible for short-term or long-term incentive awards in 2027.
Analysis
Integer Holdings is managing executive transitions in anticipation of a potential change of control. The President of a key division is moving to a temporary "Special Projects" role with a defined end date, and his separation will be treated as "without cause" if a change of control occurs before that date. This aligns with the company's previously announced strategic review to explore a sale or merger and the enhanced change-of-control provisions approved in May.
At the time of this filing, ITGR was trading at $93.89 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $3.2B. The 52-week trading range was $62.00 to $123.78. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.